Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Health Care sector as a whole closed the day up 0.9% versus the S&P 500, which was up 0.7%. Laggards within the Health Care sector included Aurinia Pharmaceuticals ( AUPH), down 4.9%, VirtualScopics ( VSCP), down 1.8%, SunLink Health Systems ( SSY), down 2.0%, Celsus Therapeutics ( CLTX), down 4.3% and EntreMed ( ENMD), down 1.8%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today:

EntreMed ( ENMD) is one of the companies that pushed the Health Care sector lower today. EntreMed was down $0.03 (1.8%) to $1.66 on average volume. Throughout the day, 27,621 shares of EntreMed exchanged hands as compared to its average daily volume of 20,800 shares. The stock ranged in price between $1.65-$1.68 after having opened the day at $1.66 as compared to the previous trading day's close of $1.69.

EntreMed has a market cap of $47.1 million and is part of the health services industry. Shares are up 1.1% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, VirtualScopics ( VSCP) was down $0.08 (1.8%) to $4.18 on light volume. Throughout the day, 1,056 shares of VirtualScopics exchanged hands as compared to its average daily volume of 4,100 shares. The stock ranged in price between $4.18-$4.20 after having opened the day at $4.20 as compared to the previous trading day's close of $4.26.

VirtualScopics, Inc. provides imaging solutions for the pharmaceutical, biotechnology, and medical device industries. VirtualScopics has a market cap of $13.0 million and is part of the health services industry. Shares are up 23.1% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates VirtualScopics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates VirtualScopics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and weak operating cash flow.

Highlights from TheStreet Ratings analysis on VSCP go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 646.3% when compared to the same quarter one year ago, falling from $0.13 million to -$0.73 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, VIRTUALSCOPICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$1.16 million or 716.90% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • This stock's share value has moved by only 7.66% over the past year. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The revenue fell significantly faster than the industry average of 21.6%. Since the same quarter one year prior, revenues fell by 28.5%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.

You can view the full analysis from the report here: VirtualScopics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Aurinia Pharmaceuticals ( AUPH) was another company that pushed the Health Care sector lower today. Aurinia Pharmaceuticals was down $0.15 (4.9%) to $2.92 on heavy volume. Throughout the day, 35,737 shares of Aurinia Pharmaceuticals exchanged hands as compared to its average daily volume of 700 shares. The stock ranged in price between $2.78-$3.35 after having opened the day at $3.07 as compared to the previous trading day's close of $3.07.

Aurinia Pharmaceuticals has a market cap of $97.2 million and is part of the health services industry. Shares are down 7.6% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Aurinia Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.